

Ynto S De Boer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4342922/publications.pdf>

Version: 2024-02-01

26
papers

1,912
citations

471509

17
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

2755
citing authors

#	ARTICLE	IF	CITATIONS
1	Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. <i>Gastroenterology</i> , 2015, 148, 1340-1352.e7.	1.3	646
2	Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. <i>Gastroenterology</i> , 2014, 147, 443-452.e5.	1.3	268
3	17 β -Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 1504-1519.	7.3	200
4	Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 103-112.e2.	4.4	144
5	HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. <i>Genes and Immunity</i> , 2015, 16, 247-252.	4.1	96
6	Assessment of the histopathological key features in autoimmune hepatitis. <i>Histopathology</i> , 2015, 66, 351-362.	2.9	68
7	Expert clinical management of autoimmune hepatitis in the real world. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 723-732.	3.7	66
8	Herbal and Dietary Supplement-Induced Liver Injury. <i>Clinics in Liver Disease</i> , 2017, 21, 135-149.	2.1	58
9	Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 640-646.	3.7	44
10	Adverse events related to low dose corticosteroids in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1120-1126.	3.7	42
11	Auto immune hepatitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 4651.	3.3	39
12	Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 940-947.e2.	4.4	36
13	Seroprevalence of Hepatitis E Virus in Autoimmune Hepatitis Patients in the Netherlands. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 9-13.	0.9	35
14	Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1616-1624.e2.	4.4	31
15	Seroprevalence of celiac disease in patients with autoimmune hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1104-1107.	1.6	29
16	The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986191.	3.2	23
17	Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 761-767.	3.7	21
18	Established and novel therapeutic options for autoimmune hepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 315-326.	8.1	17

#	ARTICLE	IF	CITATIONS
19	Cytotoxic T Lymphocyte Antigenâ€“4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis. <i>Liver International</i> , 2013, 33, 1039-1043.	3.9	15
20	TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes. <i>Gastroenterology</i> , 2018, 155, 1923-1935.e8.	1.3	11
21	Realâ€“world management of juvenile autoimmune liver disease. <i>United European Gastroenterology Journal</i> , 2018, 6, 1032-1038.	3.8	10
22	Drug withdrawal in patients with autoimmune hepatitis in long-term histological remission: A prospective observational study. <i>European Journal of Internal Medicine</i> , 2021, 90, 30-36.	2.2	5
23	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1845-1846.	4.4	4
24	A Case of Autoimmune Hepatitis and Bisphosphonate-Related Osteonecrosis of the Jaw. <i>Case Reports in Gastroenterology</i> , 2012, 6, 309-313.	0.6	3
25	Letter: allopurinol coâ€“therapy is safe and effective in autoimmune hepatitis â€“ authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 920-920.	3.7	1
26	Letter: tacrolimus may be hazardous in decompensated autoimmune liver disease with hyperbilirubinemiaâ€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1568-1569.	3.7	0